Novo Nordisk posted 2025 constant-currency sales growth of 10% and operating profit growth of 6%, in line with guidance, and set a 2026 outlook that reframes expectations for the GLP-1 era. For 2026, the company introduced new adjusted non-IFRS metrics and guided to adjusted sales and operating profit declines of 5% to 13% at constant exchange rates, reflecting lower realized prices in the United States, reduced Medicaid coverage for obesity, loss of exclusivity for semaglutide in parts of International Operations, and intensifying competition. A one-time reversal of $4.2 billion in U.S. 340B rebate provisions will lift reported—non-adjusted—results, leaving the midpoint of non-adjusted 2026 guidance at roughly flat sales and double-digit operating profit growth, but the adjusted view is the operating reality commercial teams must plan against.
The signal is clear: the GLP-1 growth supercycle is shifting from supply-constrained premium pricing to access-driven volume at lower net price. Novo’s adoption of adjusted metrics acknowledges how legal and policy shocks can obscure operating performance, yet the strategic question is simpler: can category expansion offset a structural reset in U.S. net pricing and coverage? The 340B reversal and a Most Favored Nation-style agreement with the U.S. administration on GLP-1 pricing point to a new phase where affordability commitments are table stakes and contracting sophistication, not list price, defines success.
For payers, 2026 may be the year obesity therapeutics move from exception to expectation—on their terms. Lower net prices and MFN constructs will pressure competitor contracting and could catalyze outcomes-aligned models to manage long-term cardiometabolic spend. For patients, the calculus is mixed: expanded access channels and lower out-of-pocket options in self-pay pathways may increase reach, but reduced Medicaid coverage will create inequities that Medical Affairs and policy teams will be pressed to address with real-world evidence on downstream cost offsets. For HCPs, the January 2026 U.S. launch of an oral Wegovy and the roll-out of a 7.2 mg dose in select markets complicate treatment algorithms, adherence dynamics, and titration protocols. Expect Medical Affairs to prioritize comparative effectiveness, persistence data, and guidance on switching and channel navigation as telehealth collaborations and pharmacy programs become core distribution levers.
Commercially, the U.S. outlook underscores a tougher net price environment and a likely shift in channel mix as Novo leans into NovoCare pharmacy and telehealth partners. The company flagged that 2025 gross-to-net tailwinds will not repeat, a reminder to brand teams to stress-test contracting elasticity and patient affordability design. Internationally, continued GLP-1 volume growth is real but tempered by semaglutide patent expiries and competitor advances. The category’s competitive center of gravity is tilting toward next-generation incretins, oral formulations, and fixed-dose combinations, raising the importance of lifecycle management and rapid evidence generation to defend share as generics and new entrants nibble at the edges.
Novo’s plan to invest behind obesity and diabetes R&D, including integration of assets from the Akero acquisition, suggests a broader cardiometabolic platform play beyond weight loss alone. The forward risk is whether pricing normalization arrives faster than clinical and delivery innovation can widen the value narrative. Watch three markers in 2026: the elasticity of demand for an oral obesity therapy at lower net price, payer adoption of outcomes-based frameworks for GLP-1s, and whether MFN-style constructs extend beyond obesity into other high-demand chronic therapies. The next phase belongs to those who can translate demand into durable, reimbursed care pathways without surrendering strategic margin.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
